Ocular GVHD   Diagnosis and Treatment @AAMDSIF
Ocular GVHD   Diagnosis and Treatment  @AAMDSIF
Uploaded January 2025 | Updated September 2026, 17 hours ago
In this webinar, Dr. Sandeep Jain will discuss the diagnosis and treatment of ocular GvHD which occurs in 40-60% patients following an allogenic transplant. Ocular GVHD may lead to severe ocular surface disease, which can significantly diminish quality of life and restrict daily activities. He will answer questions from participants at the end of the presentation.
Ocular GVHD   Diagnosis and TreatmentPediatric Nurse Finds her Way through Aplastic Anemia TreatmentLiving with PNH: Tamirs StoryBronchiolitis Obliterans / GVHD:TREATMENTS FOR MDS & SECONDARY AMLUpdates on Aplastic Anemia and PNH from ASH2021, ASCO2022, and EHA2022AML Session Summary for Patients with Mikkael Sekeres - Secondary AML and TransplantationAddressing Barriers and Challenges to Patient Care - 2023 Omaha Patient and Family Hybrid ConferenceNon-Transplant Therapies for Marrow Failure with Dr. Bhavisha Patel and Dr. Phillip Scheinberg2022 Webinar: When Does a PNH Clone Have Clinical Significance?AAMDSIF 40th Anniversary Summit: Advances in the Science and Treatment of PNHTransplant for MDS in Older Adults - with Mariam Nawas
AAMDSIF |

Ocular GVHD Diagnosis and Treatment

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER